The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Tag Archives: Saeed Motahari
As of April 13, 2017, more than 10.4 million shares of Insys Therapeutics (NASDAQ: INSY) were sold short. That’s 44% of the marijuana stock’s float. Investors have clearly bet big against Insys, anticipating that the stock will sink.